Drug Profile
Research programme: potassium channel agonists - Bausch Health Companies
Alternative Names: VRX 698Latest Information Update: 18 Jul 2018
Price :
$50
*
At a glance
- Originator Valeant Pharmaceuticals International
- Developer Bausch Health Companies
- Class Carbamates; Phenylenediamines; Small molecules
- Mechanism of Action KCNQ potassium channel agonists; Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Epilepsy; Neurological disorders
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 29 Feb 2012 Discontinued - Preclinical for Epilepsy in USA (unspecified route)
- 29 Feb 2012 Discontinued - Preclinical for Neurological disorders in USA (unspecified route)